Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Banc of California, Inc. stock logo
BANC
Banc of California
$18.37
-1.7%
$17.99
$13.24
$21.61
$2.75B0.752.89 million shs1.19 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.76
-7.6%
$1.41
$0.91
$2.47
$204.07M2.131.93 million shs1.01 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Banc of California, Inc. stock logo
BANC
Banc of California
+1.43%-2.51%+0.97%-6.53%+27.85%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-10.80%-21.81%+41.79%+52.00%+97.92%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Banc of California, Inc. stock logo
BANC
Banc of California
$18.37
-1.7%
$17.99
$13.24
$21.61
$2.75B0.752.89 million shs1.19 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.76
-7.6%
$1.41
$0.91
$2.47
$204.07M2.131.93 million shs1.01 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Banc of California, Inc. stock logo
BANC
Banc of California
+1.43%-2.51%+0.97%-6.53%+27.85%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-10.80%-21.81%+41.79%+52.00%+97.92%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Banc of California, Inc. stock logo
BANC
Banc of California
3.00
Buy$21.8318.89% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.17
Hold$5.50213.39% Upside

Current Analyst Ratings Breakdown

Latest FATE and BANC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
UpgradeSell (E+)Sell (D-)
5/4/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Boost Price TargetBuy$5.00 ➝ $7.00
4/29/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
DowngradeSell (D-)Sell (E+)
4/28/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Reiterated RatingBuy$24.00
4/27/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Boost Price TargetOverweight$22.00 ➝ $23.00
4/24/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Boost Price TargetOverweight$20.50 ➝ $22.00
4/7/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Lower Price TargetOverweight$25.00 ➝ $23.00
4/2/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Lower Price TargetOverweight$25.00 ➝ $22.00
4/1/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Lower Price TargetOverweight$25.00 ➝ $20.50
3/30/2026
Banc of California, Inc. stock logo
BANC
Banc of California
Boost Price TargetOverweight$20.00 ➝ $22.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Banc of California, Inc. stock logo
BANC
Banc of California
$1.82B1.52$1.95 per share9.42$20.36 per share0.90
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$6.65M30.69N/AN/A$1.80 per share0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Banc of California, Inc. stock logo
BANC
Banc of California
$228.97M$1.3113.998.75N/A13.58%9.25%0.81%7/22/2026 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$136.32M-$1.15N/AN/AN/A-2,056.79%-55.47%-37.68%N/A

Latest FATE and BANC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million
4/22/2026Q1 2026
Banc of California, Inc. stock logo
BANC
Banc of California
$0.3761$0.39+$0.0139$0.39$291.28 million$286.95 million
2/26/2026Q4 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.27-$0.27N/A-$0.27$1.20 million$1.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Banc of California, Inc. stock logo
BANC
Banc of California
$0.482.61%+10.76%36.64%N/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A

Latest FATE and BANC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2026
Banc of California, Inc. stock logo
BANC
Banc of California
quarterly$0.122.52%6/15/20266/15/20267/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Banc of California, Inc. stock logo
BANC
Banc of California
0.31
0.89
0.89
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
5.79
5.79

Institutional Ownership

CompanyInstitutional Ownership
Banc of California, Inc. stock logo
BANC
Banc of California
86.88%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%

Insider Ownership

CompanyInsider Ownership
Banc of California, Inc. stock logo
BANC
Banc of California
2.78%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Banc of California, Inc. stock logo
BANC
Banc of California
1,904150.04 million145.87 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550116.28 million110.77 millionOptionable

Recent News About These Companies

Fate Therapeutics (FATE) to Release Earnings on Tuesday
Earnings Summary: Fate Therapeutics Q4

New MarketBeat Followers Over Time

Media Sentiment Over Time

Banc of California stock logo

Banc of California NYSE:BANC

$18.36 -0.32 (-1.69%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Banc of California, Inc. operates as the bank holding company for Banc of California that provides various banking products and services in California. The company offers deposit products, such as checking, savings, money market, demand, and time deposits; certificates of deposit; retirement accounts; and safe deposit boxes. It also provides real estate loans to professional developers and real estate investors for the acquisition, construction, refinancing, renovation, and on-going operation of commercial real estate properties; commercial real estate mortgage, residential real estate mortgage, and real estate construction and land loans; commercial loans and leases, such as equipment finance, other asset-based, venture capital, secured business, warehouse, and other lending services; small business administration loans; and consumer loans comprising personal, auto, and other loans, as well as home equity and revolving lines of credit. In addition, the company offers international banking, multi-state deposit, and asset and investment management services, as well as cash and treasury management services; and online, mobile, remote deposit, and telephone banking services. It serves small and middle-market businesses, venture capital firms, non-profit organizations, business owners, entrepreneurs, professionals, and high-net worth individuals. Banc of California, Inc. was founded in 1941 and is headquartered in Los Angeles, California.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$1.76 -0.15 (-7.63%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.